Alpha 2.0
Login Register
» Authors » P Bias

P Bias

Explore the profile of P Bias including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 8
Citations 105
Followers 0
Related Specialties
Pharmacology
General Medicine
Oncology
Top 10 Co-Authors
A Buchner
P Kes
C Behrens
A Essaian
E Kohler
G Illerhaus
A Kohler
J Martel-Pelletier
D Choquette
M Engelhardt
Published In
Curr Med Res Opin
Aliment Pharmacol Ther
Support Care Cancer
Fortschr Med
Ann Rheum Dis
Affiliations
Soon will be listed here.
Recent Articles
1.
Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study
Link H, Illerhaus G, Martens U, Salar A, Depenbusch R, Kohler A, et al.
Support Care Cancer . 2020 Sep; 29(5):2519-2527. PMID: 32944800
Background: Lipegfilgrastim has been shown to be non-inferior to pegfilgrastim for reduction of the duration of severe neutropenia (DSN) in breast cancer patients. This open-label, non-inferiority study assessed the efficacy...
2.
Incidence of bone pain in patients with breast cancer treated with lipegfilgrastim or pegfilgrastim: an integrated analysis from phase II and III studies
Bondarenko I, Bias P, Buchner A
Support Care Cancer . 2015 May; 24(1):267-273. PMID: 26024743
Purpose: Lipegfilgrastim is a once-per-cycle, fixed-dose, glycoPEGylated recombinant granulocyte colony-stimulating factor (G-CSF) recently approved in Europe to reduce the duration of chemotherapy-induced neutropenia and incidence of febrile neutropenia in patients...
3.
Epoetin theta: efficacy and safety of subcutaneous administration in anemic pre-dialysis patients in the maintenance phase in comparison to epoetin beta
Gertz B, Kes P, Essaian A, Bias P, Buchner A, Zellner D
Curr Med Res Opin . 2012 Apr; 28(7):1101-10. PMID: 22533679
Objective: To compare the efficacy and safety of epoetin theta and epoetin beta in anemic patients with chronic kidney disease (CKD) not yet receiving dialysis and previously on stable maintenance...
4.
Epoetin theta: efficacy and safety of IV administration in anaemic haemodialysis patients in the maintenance phase in comparison to epoetin beta
Gertz B, Kohler E, Kes P, Essaian A, Bias P, Buchner A, et al.
Curr Med Res Opin . 2010 Sep; 26(10):2393-402. PMID: 20812790
Objective: To compare the efficacy and safety of epoetin theta and epoetin beta in anaemic patients with chronic kidney disease, undergoing haemodialysis and previously on stable maintenance therapy with epoetin...
5.
Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI
Raynauld J, Martel-Pelletier J, Bias P, Laufer S, Haraoui B, Choquette D, et al.
Ann Rheum Dis . 2008 Jul; 68(6):938-47. PMID: 18653484
Objective: In a multicentre study to explore the effects of licofelone as a disease-modifying osteoarthritis drug in comparison with naproxen in patients with knee osteoarthritis (OA), using MRI and x-ray...
6.
Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis--results from a randomized-controlled trial
Raedler A, Behrens C, Bias P
Aliment Pharmacol Ther . 2004 Dec; 20(11-12):1353-63. PMID: 15606398
Background: Formulations containing 5-aminosalicylic acid, such as mesalazine, are the gold standard of treatment for mild-to-moderate ulcerative colitis. Current oral regimens require the use of large tablets and frequent dosing...
7.
Combined scintigraphic and pharmacokinetic investigation of enteric-coated mesalazine micropellets in healthy subjects
Wilding I, Behrens C, Tardif S, Wray H, Bias P, Albrecht W
Aliment Pharmacol Ther . 2003 May; 17(9):1153-62. PMID: 12752352
Background: There is a growing clinical trend to increase the daily dose of mesalazine, which leads to significant compliance issues associated with multiple dosings of current preparations. Aim: To examine...
8.
[Dimethylsulfoxide (DMSO) gel in treatment of acute tendopathies. A multicenter, placebo-controlled, randomized study]
Kneer W, Kuhnau S, Bias P, Haag R
Fortschr Med . 1994 Apr; 112(10):142-6. PMID: 8194818
Method: In a placebo-controlled double-blind study, 157 patients with acute tenopathies (periarthropathia humeroscapularis or lateral epicondylitis) were randomized to treatment with either DMSO gel 10% applied three times a day...